Health Care Roundup: Market Talk

Dow Jones11-18 01:20

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0923 ET - EssilorLuxottica faces a lack of immediate growth drivers alongside governance uncertainty caused by internal family disputes at its holding company, HSBC analysts write. Despite this, HSBC says the Franco-Italian company can perform strongly, with improved visibility from the newly provided sales breakdown between its units. HSBC cuts its rating on the stock to hold from buy and the target price to 190 euros from 200 euros. Shares are down 2.7% at 179.45 euros and 33.5% lower over the year to date. (ian.walker@wsj.com)

0457 ET - Siemens Healthineers is moving in the right direction, but its transformation isn't yet complete and still carries risks, Berenberg analysts say in a research note. The German medical-technology company has launched a carve-out process for its diagnostics business while it advances toward a spinoff from engineering giant Siemens. Both might loom over Healthineers's stock into early next year, Berenberg says. "We think [the spinoff] will remain an overhang on the shares until signed off, with potential volatility in the share price thereafter given that some Siemens AG investors may look to sell the Healthineers shares they receive immediately," the analysts say. Shares fall 1%. (adria.calatayud@wsj.com)

0431 ET - Roche Holding got U.S. approval for its new drug Wilserdly in advanced breast cancer four weeks ahead of schedule, but the medicine's label includes warnings and precautions that weren't expected, RBC Capital Markets analysts say in a research note. The Swiss drugmaker is awaiting approval for Wilserdly in the larger early-disease setting, but the approval for locally advanced or metastatic breast cancer is a key first step, the analysts say. That said, the medicine's label includes warnings and precautions for bradycardia and embryofetal toxicity, the analysts say. Moreover, Wilserdly has been approved for now for patients with a resistance mutation to an earlier treatment, which limits the initial commercial opportunity somewhat, RBC says. Shares fall 0.4%.(adria.calatayud@wsj.com)

0424 ET - Roche Holding won its first U.S. approval for breast-cancer drug Wilserdly, which has the potential to become a new major oncology drug for the Swiss pharmaceutical company, Vontobel's Stefan Schneider says in a note. "The approval strengthens Roche's growth outlook in breast cancer and could be followed by a larger opportunity in early-stage disease," Schneider says. The Food and Drug Administration is due to decide on Wilserdly's authorization in an earlier-stage disease setting by Nov. 30. If approved, the drug would become the first of its kind approved in both advanced and early breast cancer, substantially expanding its commercial potential, the analyst says. The market likely priced in both approvals, he adds. Roche shares fall 0.4%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment